{
    "Trade/Device Name(s)": [
        "ImmuLisa Enhanced AMA IgG Antibody ELISA",
        "ImmuLisa Enhanced AMA IgA/IgG/IgM Antibody ELISA"
    ],
    "Submitter Information": "IMMCO Diagnostics, Inc.",
    "510(k) Number": "K163133",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DBM"
    ],
    "Summary Letter Date": "August 8, 2017",
    "Summary Letter Received Date": "July 5, 2017",
    "Submission Date": "June 27, 2017",
    "Regulation Number(s)": [
        "21 CFR 866.5090"
    ],
    "Regulation Name(s)": [
        "Antimitochondrial antibody immunological test system"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "Anti-mitochondria IgG antibodies",
        "Anti-mitochondria IgA antibodies",
        "Anti-mitochondria IgM antibodies"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked immunosorbent assay (ELISA)",
        "Solid phase immunoassay"
    ],
    "Methodologies": [
        "Antibody detection by immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for IMMCO Diagnostics ImmuLisa Enhanced AMA IgG and IgA/IgG/IgM ELISA assays for detection of anti-mitochondria antibodies in human serum for primary biliary cirrhosis diagnosis",
    "Indications for Use Summary": "Qualitative or semi-quantitative detection of anti-mitochondria antibodies (IgG and IgA/IgG/IgM) in human serum to aid in the diagnosis of primary biliary cirrhosis (PBC) in conjunction with other laboratory tests and clinical findings",
    "fda_folder": "Immunology"
}